Basking Biosciences

Basking Biosciences is a clinical-stage biopharmaceutical company developing therapies for acute thrombotic conditions. Its lead candidate, BB-031, is an RNA aptamer that inhibits von Willebrand Factor (vWF), a mediator of clot initiation, growth and stabilization, and is engineered for rapid onset and short duration of effect. BB-031 is paired with BB-025, a direct-acting reversal oligonucleotide designed to rapidly and durably neutralize BB-031's pharmacological activity. The company positions the pair as a way to broaden the population of patients eligible for thrombolytic intervention, since existing therapies have limited effectiveness, safety risks, narrow treatment windows, or require specialized care.

The program originated in translational research on RNA aptamers for cardiovascular disease conducted in the laboratory of Bruce Sullenger at Duke, and is co-founded by Shahid M. Nimjee, a neurosurgeon at The Ohio State University Wexner Medical Center whose laboratory studies anti-vWF aptamers and their antidotes in thromboembolic stroke. BB-031 has also been referred to as DTRI-031, with BB-025 referred to as DTRI-025.

Clinically, the company reported positive Phase 1 safety and dose-escalation results for BB-031 in 2023, dosed the first patients in the Phase 2 RAISE proof-of-concept trial in acute ischemic stroke in September 2024, dosed first patients in Part B of the Phase 2 trial in October 2025, and began first-in-human dosing of BB-025 in November 2025.